Literature DB >> 16760225

Validity of melanoma diagnosis in a community-based screening program.

Lin Fritschi1, Sarah A Dye, Paul Katris.   

Abstract

Although screening for melanoma is intuitively attractive, evidence of the effectiveness of screening programs for skin cancer is lacking. Since 1990, the Lions Cancer Institute has conducted clinics in Western Australia in which volunteer plastic surgeons and dermatologists undertake full-body skin screens. Advertisements for attendees target people with risk factors for skin cancer. Each person screened between 1994 and 2002 (n = 7,436) completed a questionnaire including basic demographic information, on which the physician added provisional diagnoses. Attendees' details were linked with the Western Australian Cancer Registry to determine the number of diagnosed melanomas up to 1 and 2 years after screening. The positive predictive value of a screening diagnosis of "any lesion" at a particular body site was 1.5% and that of a screening diagnosis of "melanoma" was 10.0%. The 1-year specificity of the screening test ranged from 95.1% to 99.5%, and 1-year sensitivity ranged from 63.6% to 81.8%. Two-year sensitivity was lower. If body site was not taken into account, the sensitivities were higher and the specificities lower. Findings suggest that the validity of skin screening diagnoses in the general population is reasonable. Body site of the lesion should be taken into account when calculating validity of these diagnoses.

Entities:  

Mesh:

Year:  2006        PMID: 16760225     DOI: 10.1093/aje/kwj204

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  2 in total

1.  Screening for Melanoma in Men: a Cost-Effectiveness Analysis.

Authors:  Adewole S Adamson; Jamie A Jarmul; Michael P Pignone
Journal:  J Gen Intern Med       Date:  2019-11-08       Impact factor: 5.128

2.  Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia.

Authors:  Anna Kemp; David B Preen; Christobel Saunders; C D'Arcy J Holman; Max Bulsara; Kris Rogers; Elizabeth E Roughead
Journal:  BMC Med Res Methodol       Date:  2013-02-11       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.